about
sameAs
Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosisImproving the characterization of radiologically isolated syndrome suggestive of multiple sclerosisNew and emerging disease modifying therapies for multiple sclerosisFingolimod for relapsing-remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisWhole-body vibration training for patients with neurodegenerative diseaseInterferon beta for secondary progressive multiple sclerosisStatins for multiple sclerosisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisStatins for multiple sclerosisFingolimod for relapsing remitting multiple sclerosisStatins for multiple sclerosisInterferon beta for secondary progressive multiple sclerosisCorticosteroids for the long-term treatment in multiple sclerosisMagnetic resonance spectroscopic findings of chronic lesions in two subtypes of multiple sclerosis: primary progressive versus relapsing remittingNitric oxide and peroxynitrite in health and diseaseThe endocannabinoid system as an emerging target of pharmacotherapyReproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patientsGeographical and seasonal correlation of multiple sclerosis to sporadic schizophreniaMatrix Metalloproteinases in Non-Neoplastic Disorders.Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple SclerosisImpact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyCNS Remyelination and the Innate Immune SystemmiRNAs Participate in MS Pathological Processes and Its Therapeutic ResponseDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsUrinary Biomarkers of Brain DiseasesMesenchymal stem cells for the treatment of neurodegenerative and psychiatric disordersOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionFunctional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple SclerosisRole of prostaglandins in neuroinflammatory and neurodegenerative diseasesReview of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaGender disparities in ocular inflammatory disordersMast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitisThe Evi5 family in cellular physiology and pathologyNeuroprotective effects of estrogens and androgens in CNS inflammation and neurodegenerationHyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarizationSecondary and tertiary treatments for multiple sclerosis patients with urinary symptomsHematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?
P2860
Q21261507-6FA07C86-24C5-4AD9-9AED-6A04BC8673DAQ21560827-85E66044-DC14-464B-9255-D7F7243018DDQ22242305-E6E2D4A5-B980-4BDB-B7A8-5AB42FA9B237Q24185882-008B5A03-43EF-4E45-A1DA-244B4C53ECCFQ24200496-439564AA-5764-4EF8-8D6B-2FA7061CEBECQ24201637-ECFF5CA0-02F6-47DC-8B0C-5A4E4F9D23C9Q24202108-3C0F53C2-401D-46D8-83FC-0F980B35DC68Q24203703-A72E7BCF-6A27-4CAF-AF66-90CA66F2F006Q24203879-127FA165-28E3-4890-8EF1-BE874D8FBFF2Q24234119-14F98D27-2A00-42E9-8404-1007A2ABE163Q24235249-25B0EA49-006E-4754-8D13-6DA51392A026Q24235592-7DCD4607-DE9F-43FB-90E6-813AA7652147Q24236597-5715CDF9-C6C7-40DA-97D0-5085EB4AF7E5Q24240191-E0AAB258-56C5-49A7-9986-90006168ED6DQ24240509-C2CFDBF7-547C-4815-9C0D-50078A46CBEFQ24242150-C04B1ACC-A4B9-4B2B-A714-F75F0838A39BQ24630939-7DC2E953-1E46-4935-8594-E5BB62A24D32Q24645400-B490D875-4F0A-4C80-9539-C349263F580EQ24648473-E85A8B3A-A64D-4E5F-94EC-88F4D3CAD3EBQ24657825-C72DA3D0-EB0C-4294-8ACE-D6E2F8848E9CQ24799677-618380DE-B547-498C-8D01-23AE06AAFACEQ26741827-DB5E0A27-DF49-4F42-BE93-924288BFC762Q26744629-D8EF0139-F680-45F1-BFA9-896411285DC0Q26745562-BB8B8719-4907-4F31-BEF0-FFE8F990BD6CQ26747242-0F37F558-1A57-4E4C-AF4B-BEA5A0ECA9F5Q26748774-6577C742-5196-474B-A218-36EAE6AE3E64Q26752859-FBB3C151-6F76-4D67-9925-BF13575A5AE3Q26769944-56B45AE1-98B4-4000-A280-659854174B1FQ26801575-34CEB473-9639-4663-9031-F945059686A5Q26822611-51D226C3-9810-4CF1-A452-660FEF394577Q26824972-29186BF7-5D8B-4ED6-B9D7-C1A2D57E14A5Q26863534-8539C76F-7772-4C1B-B922-23929AEE578DQ26864418-BFAF3C3B-550D-49F5-9D96-EEDCC31031B6Q26995402-A1D7D8F0-89D1-4612-A4FF-BD0C64685505Q26995490-3F003919-D3CD-447C-A30C-35BE5785C9A9Q27013381-7C65576D-CB61-4CDC-9334-B7E2BE1C8A82Q27023974-110C485F-92FF-4360-AFC6-07D9676CBD02Q27316627-DB1470C6-E090-4322-9B4A-AB4870B28C55Q28070040-CA243D7A-FD2F-429D-BC94-4171249C1695Q28071992-5E2BA481-23F9-412A-9C2F-8DCAA3B24F2C
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Multiple sclerosis
@ast
Multiple sclerosis
@en
Multiple sclerosis
@nl
type
label
Multiple sclerosis
@ast
Multiple sclerosis
@en
Multiple sclerosis
@nl
prefLabel
Multiple sclerosis
@ast
Multiple sclerosis
@en
Multiple sclerosis
@nl
P3181
P1433
P1476
Multiple sclerosis
@en
P2093
Alasdair Coles
P304
P3181
P356
10.1016/S0140-6736(02)08220-X
P407
P577
2002-04-06T00:00:00Z